-
Novartis Application for Expanded Menveo Indication from 2 Months of Age Accepted for Review by FDA
Thursday, June 16, 2011 - 7:16am | 59Novartis (NYSE: NVS) announced today that the US Food and Drug Administration has accepted for review its supplemental Biologics License Application to expand the Menveo indication to include infants and toddlers from 2 months of age. Menveo is already approved in the US for use in individuals 2...
-
Stocks to Watch for 6/16/11: Fresh 52-Week Highs and Lows
Thursday, June 16, 2011 - 2:28am | 2229The following stocks hit new 52-week highs in Wednesday's trading session 1) Ulta Salon, Cosmetics & Fragrances (NASDAQ: ULTA): Shares of Ulta hit a 52-week high of $59.40 in Wednesday's trading session. The stock closed at $57.03. The year-to-date performance of Ulta has been a gain of 67.7...
-
Options Brief: Eli Lilly and Company
Wednesday, June 15, 2011 - 1:54pm | 77Shares of Eli Lilly and Company (NYSE: LLY) are lower on the session by 1.06%, trading at $37.21. Overall call volume is now running at 2.48x the daily average, with 41% of all calls traded being purchases on the offer. 9,921 contracts have traded on the session so far. Eli Lilly and Company...
-
ViroPharma's Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema
Wednesday, June 15, 2011 - 10:33am | 142ViroPharma Incorporated (Nasdaq: VPHM) today announced that the European Commission has granted ViroPharma Centralized Marketing Authorization for Cinryze® (C1 inhibitor [human]) in adults and adolescents with hereditary angioedema (HAE) for routine prevention, pre-procedure prevention and acute...
-
Calls Purchased on Sanofi-Aventis
Wednesday, June 15, 2011 - 10:23am | 121Shares of Sanofi-Aventis (NYSE: SNY) are lower on the session by 2.97%, currently trading at $37.25. The stock has been moving largely higher over the past five months and is currently trading above the 200-day moving average. Options traders are buying calls on the name today. A short while ago...
-
Stocks Hitting 52-Week Highs
Wednesday, June 15, 2011 - 10:22am | 147Fundtech Ltd (NASDAQ: FNDT) shares rose 1.23% to create a new 52-week high of $20.53. FNDT announced a cash dividend of $0.10 per share for June. Pharmacyclics Inc (NASDAQ: PCYC) shares gained 0.33% to create a new 52-week high of $8.91. PCYC had $54.41 million in total cash and no debt for the...
-
Perrigo Announces Launch of the Generic Version of Nasacort AQ
Wednesday, June 15, 2011 - 9:14am | 159Perrigo Company (Nasdaq: PRGO) today announced that its partner Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) has begun shipping Triamcinolone Acetonide Nasal Spray. Perrigo's partner Teva was the first applicant to file a complete ANDA with a Paragraph IV certification for Nasacort AQ and...
-
Johnson & Johnson Announces Special Charge of $500-$600 Million Related to Restructuring Plans for Cordis Corporation Subsidiary
Wednesday, June 15, 2011 - 9:03am | 103Johnson & Johnson (NYSE: JNJ) today announced that it expects to record an after-tax restructuring charge in the range of $500-$600 million in the second quarter of 2011 as a result of restructuring plans announced by its subsidiary, Cordis Corporation. The restructuring charge will be treated...
-
Boehringer Ingelheim and Eli Lilly's New Type 2 Diabetes Treatment Tradjenta Tablets for Adults Now Available in U.S. Pharmacies
Wednesday, June 15, 2011 - 9:01am | 102Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced Tradjenta tablets are now available by prescription in pharmacies across the United States including Walgreens, CVS, Rite Aid and many leading chain and independent pharmacies. The U.S. Food and Drug...
-
The 8 Most Appropriate Strategies
Wednesday, June 15, 2011 - 8:07am | 926Cullen Roche posted the following list from David Rosenberg for this "ailing" market (hat tip to a tweet from David Merkel). Hedge fundsDividend StrategiesLong oil, gold, raw foodReduce base metal exposuresShort the EuroDefensive sectorsLow levels of leverage/riskFocus on quality and liquidity The...
-
Warner Chilcott, Valeant Pharmaceuticals Share Several Attractive Attributes, Bank of America Reports
Wednesday, June 15, 2011 - 7:44am | 150In addition to being large Specialty Pharma companies, Bank of America reports that “Warner Chilcott plc (NASDAQ: WCRX) and Valeant Pharmaceuticals International, Inc. (NYSE: VRX) share several attractive attributes, including high margins, strong cash flow generation, and favorable tax structures...
-
Spectrum Pharmaceuticals Announces Authorization of Stock Repurchase Program up to $25M
Wednesday, June 15, 2011 - 7:02am | 88Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) today announced that its Board of Directors has authorized the purchase of up to $25 million of its common stock through the end of 2012. Stock will be purchased from time to time, in the open market, through block trades, through 10b5-1 plans, or...
-
Mad Money Lightning Round OT: Cramer Thinks That FRX Is A Buy (FRC, CYN, IGT, WYNN, FRX)
Tuesday, June 14, 2011 - 7:36pm | 213On CNBC's Mad Money Lightning Round OT, Jim Cramer said that First Republic Bank (NYSE: FRC) is a great bank, and he would hold on that stock. It is not hurt by the problems that other banks are facing. He also likes City National Corporation (NYSE: CYN). First Republic Bank (FRC) gained 1.69%...
-
Watson Confirms Pataday Patent Challenge
Tuesday, June 14, 2011 - 4:58pm | 167Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration (FDA) seeking approval to market Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%. Watson's...
-
Adolor Corporation Announces Agreement to Acquire Full Ownership of ENTEREG
Tuesday, June 14, 2011 - 4:41pm | 128Adolor Corporation (Nasdaq: ADLR) today announced that it has entered into an agreement with GlaxoSmithKline (GSK) whereby Adolor will reacquire all rights to Adolor's FDA-approved product ENTEREG. The transaction is expected to close in September 2011. Currently, ENTEREG is co-promoted by Adolor...